Factors associated with response to talimogene laherparepvec in the treatment of advanced melanoma

• DOI: 10.36922/mi.3445
• Publication Date: 2024-06-04T09:30:39Z
• Authors: Anupama Balasubra...; Michela Salusti-S...; Peter Callas; Conor O’Neill; Hibba Rehman; Shahid Ahmed; Mirabelle Sajisevi; Christopher J. Anker; Jessica Cintolo-G...
• Keywords: Complete response

Talimogene laherparepvec (T-VEC) is currently the only United States Food and Drug Administration-approved intralesional therapy for advanced melanoma. Recent studies have assessed integration of T-VEC with systemic immunotherapy, though response remains variable. Therefore, we sought to identify factors associated by conducting a retrospective, single-center analysis involving melanoma patients treated T-VEC. In present study, recorded demographic clinicopathological data, details treatments, prior concurrent clinical outcomes. The primary endpoint was in-field overall rate (ORR: complete + partial). Secondary endpoints included response, defined as resolution disease or negative biopsy; failure-free survival (DFFS), from initiation treatment time progression in who did not experience disease-free interval recurrence those did; (OS). We used two-sample t-tests continuous variables Fisher’s exact test categorical variables. DFFS OS were further analyzed using Kaplan–Meier method log-rank tests selected Among 18 met inclusion criteria, an observed 14 (78%) patients. Low burden (<5 lesions total diameter <5 cm) higher ORR compared high-burden (100% vs. 43%, P = 0.01). There trend toward decreased >2 lines (P 0.18). With median follow-up 386 days, BRAF wild-type 0.04), 0.007), measurable bystander Two more immunotherapy poorer 0.006) worse 0.02). conclusion, despite low sample size, identified covariates ORR, DFFS, OS, warranting study.